The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Abdullah HM, Narayana Gowda S, Sharma R, Ellithi M, Oberoi M

Temozolomide-Associated Organizing Pneumonia.

American journal of therapeutics. 2022;29(6):e781-e783

Koschel D, Handzhiev S, Leucht V, Holotiuk O, Fisseler-Eckhoff A, Höffken G

Hypersensitivity pneumonitis associated with the use of temozolomide.

The European respiratory journal. 2009;33(4):931-4

Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, Malkin MG

A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.

Journal of neuro-oncology. 2001;53(3):259-65